Medical Device SBOM Audits Are Halting Premarket Approvals

AdvancedUNO
13 Jul, 2026
Medical Device SBOM Audits Are Halting Premarket Approvals

8 min read

Operational Realities of Device Transparency

  • The Definition: A medical device Software Bill of Materials (SBOM) is a machine-readable, nested inventory detailing every third-party component, open-source library, and operating system dependency embedded within a device's firmware or software.
  • Why It Matters: Under Section 524B of the Consolidated Appropriations Act, 2023, the FDA has active authority to issue a Refuse to Accept (RTA) decision, immediately stopping the commercialization of any connected device lacking comprehensive security documentation.
  • The Catch: Generating a raw list of software ingredients is relatively simple, but normalizing that data to accurately map active, reachable vulnerabilities without drowning engineering teams in false positives remains a broken, highly manual process.

Why Does a Clean Inventory Halt a Premarket Medical Device Submission?

The FDA is actively turning away medical devices at the door because manufacturers cannot produce a clean, verifiable Software Bill of Materials. For years, product security in clinical engineering was treated as a secondary concern, a post-market patch applied only when a researcher exposed a vulnerability in a hospital's wireless network. That era of voluntary guidelines ended when the federal government granted the agency explicit statutory authority to police the software supply chain of connected clinical hardware.

When a premarket notification under Section 510(k) or a premarket approval (PMA) application reaches the regulatory desk, the presence of connected software triggers a strict review. Under the statutory definition, any "cyber device" — meaning any medical device that includes software and has the capability to connect to the internet, a local network, or a cellular network — must meet rigid cybersecurity baselines. If the submission lacks a validated SBOM, the review stops before it even begins, resulting in a costly Refuse to Accept (RTA) ruling that delays market entry by months.

This regulatory shift exposes a deep chasm between design-phase engineering and long-term systems thinking. Many medtech startups and mid-sized device makers suffer from severe prioritization debt, having rushed prototypes to clinical trials while treating software security as an IT checklist item to be completed later. Now, those same companies are finding that their clinical data is spotless, but their software supply chain is an unmapped maze of legacy open-source libraries, many of which have been abandoned by their original developers.

The Friction of Normalizing Machine-Readable Software Dependencies

The core challenge of managing an SBOM is not generation; it is translation. During active development, software compilation tools can automatically output a list of dependencies in standard formats like SPDX (Software Package Data Exchange) or CycloneDX. However, when these files are ingested by vulnerability scanners, the lack of standardized naming conventions creates immediate chaos in the security operations center.

An SBOM functions like a food ingredient label where every chemical preservative must list its own sub-ingredients and suppliers, yet every supplier uses a slightly different name for the same molecule. In software, one library might be listed as "openssl" in one component, "openssl-wiki" in another, and "libssl-dev" in a third-party operating system package. Without strict data normalization, vulnerability databases cannot accurately correlate these components to known Common Vulnerabilities and Exposures (CVEs), leading to missed threats or hundreds of false alarms that drain engineering hours.

The Vulnerability Mapping Trap of Static Inventories

A static SBOM is obsolete the moment the build pipeline completes. While the physical components of a syringe pump remain unchanged for years, the software vulnerabilities associated with its embedded Linux kernel change daily. If an engineering team simply exports a JSON file and attaches it to their regulatory filing, they are presenting a single snapshot of a moving target.

"An SBOM is not a static certificate of health; it is a dynamic ledger of dependency risk that requires continuous, automated reconciliation."

To bridge this gap, modern product security platforms must continuously map SBOM components against live vulnerability feeds like the National Vulnerability Database (NVD) and CISA's Known Exploited Vulnerabilities (KEV) catalog. Specialized tools are emerging to handle this lifecycle. For example, Enlil, a unified product lifecycle traceability platform, has partnered with Interlynk to connect SBOM management with active vulnerability monitoring and AI model traceability. This integration allows manufacturers to trace a software component from its source code commit, through regulatory validation, and into post-market surveillance.

A Five-Step Sequence to Transition From Spreadsheets to Automated SBOM Pipelines

Moving from manual, ad-hoc spreadsheet tracking to an automated, regulatory-compliant software supply chain pipeline requires a deliberate sequence. Trying to automate everything at once usually results in broken builds and developer mutiny. The following sequence represents an operator's blueprint for establishing a reliable SBOM lifecycle in a representative clinical hardware portfolio.

  1. Integrate Build-Time Generation: Move SBOM creation out of the post-build security audit phase and place it directly inside the active CI/CD pipeline. Use automated tools like Syft or the Microsoft CycloneDX Generator to produce a fresh SBOM every time the software compiles, ensuring that every development branch has an accurate, machine-readable inventory.
  2. Normalize Component Identifiers: Pass the raw build-time SBOM through a normalization engine to resolve naming discrepancies. Enforce the use of Package URLs (purls) and Common Platform Enumeration (CPE) strings for every third-party library, which eliminates naming ambiguity before the data is analyzed for vulnerabilities.
  3. Automate Vulnerability Mapping: Connect the normalized SBOM to a continuous monitoring platform that queries the NVD and threat intelligence feeds. This step replaces manual CVE searches with automated alerts, flagging new security issues within minutes of their public disclosure.
  4. Implement Vulnerability Exploitability eXchange (VEX): Establish a formal triaging workflow to determine if a flagged vulnerability is actually reachable within the device's specific architecture. Use VEX documents to formally declare whether a vulnerability is exploitable, allowing engineers to document that a highly publicized bug is neutralized by hardware-level read-only memory protections or network segmentation.
  5. Establish a Post-Market Surveillance Loop: Create an automated feedback loop that alerts the clinical support and product engineering teams when a critical vulnerability is discovered in the field. This step ensures compliance with post-market monitoring requirements under both FDA Section 524B and the EU Cyber Resilience Act (CRA).

The Uneven Shift From Static Compliance to Continuous Lifecycle Security

The medical device industry is currently trapped in a half-finished migration. On one side, forward-thinking manufacturers are building fully automated pipelines that treat software security as an extension of quality management. On the other side, legacy device makers are dragging their feet, attempting to meet regulatory demands by manually editing Excel spreadsheets and hoping the FDA reviewers do not look too closely at their third-party dependencies.

This resistance is not entirely driven by laziness; it is rooted in supply chain leverage. Device manufacturers often purchase proprietary software modules — such as real-time operating systems (RTOS) or proprietary networking stacks — from third-party vendors who refuse to disclose their own software ingredients. These vendors guard their source code as proprietary intellectual property, leaving the medical device manufacturer in an impossible position: they cannot compile an accurate SBOM because their suppliers refuse to give them the data. This standoff is beginning to break as major hospital purchasing groups demand SBOMs as a condition of procurement, forcing upstream suppliers to comply or lose market access.

Geopolitical pressures are further complicating this transition. A pending Senate bill seeks a comprehensive cybersecurity review and potential recall of Chinese-made medical devices used in US healthcare systems. This legislative push means that knowing *what* software components are in a device is no longer enough; manufacturers must also prove *where* those components were developed. This requirement turns the SBOM from a simple security tool into a critical instrument of geopolitical risk management, forcing companies to audit their software supply chains for components originating from state-influenced entities.

Where Static Tracking Actually Holds Up

Despite the push for continuous automation, there are specific scenarios where high-frequency, automated SBOM pipelines create more operational friction than value. For low-complexity, non-connected, single-use clinical software systems — such as a standalone desktop application used to calibrate physical therapeutic equipment in a controlled lab environment — the software attack surface is highly constrained. In these isolated environments, a static, point-in-time SBOM audit performed at the end of each major release cycle is often sufficient. Forcing these teams to maintain continuous, real-time vulnerability monitoring pipelines can lead to alert fatigue and divert scarce engineering resources away from high-risk, network-adjacent medical devices where active exploitation is a real-world threat.

Operational Blind Spots in Medical Device Supply Chain Security

  • Believing an SBOM is a one-time premarket submission artifact: The reality is that post-market surveillance requires continuous monitoring of the SBOM against new CVEs for the entire device lifecycle. If a vulnerability is discovered three years after a device is cleared, the manufacturer is still legally obligated to evaluate the risk and issue a patch or mitigation.
  • Assuming all listed vulnerabilities require immediate patching: The reality is that over 80% of identified CVEs in a typical embedded system are unreachable or non-exploitable in the device's specific configuration. Rushing to patch every minor vulnerability without performing reachability analysis introduces regression risks that can compromise device stability and patient safety.
  • Treating AI models and proprietary algorithms as exempt from the bill of materials: Modern Software-as-a-Medical Device (SaMD) platforms increasingly incorporate machine learning models. These models require tracking model weights, training datasets, and pipeline dependencies as part of the software supply chain, a requirement that is explicitly addressed by integrated platforms like Enlil and Interlynk.

Frequently Asked Questions

What happens to our premarket submission if a legacy third-party library in our firmware has no known CPE or PURL representation?

If a legacy component lacks a standardized Common Platform Enumeration (CPE) or Package URL (purl), the premarket submission will likely flag an error during automated ingestion by the FDA's validation tools. To resolve this, manufacturers must manually define a custom component entry within their CycloneDX or SPDX schema, documenting the vendor name, exact version, and source code repository. Additionally, you must provide a documented risk assessment in your cybersecurity submission explaining how this unmapped component is isolated from network-facing interfaces to prevent unauthenticated access.

How do we handle SBOM disclosures for proprietary third-party software when the vendor refuses to provide a component breakdown due to intellectual property concerns?

When a third-party vendor refuses to provide a component breakdown, you cannot simply leave a blank space in your SBOM. You must utilize binary analysis tools from vendors like Finite State or Netrise to perform "black-box" decomposition of the compiled software binary, extracting as much dependency data as possible. If gaps remain, you must document a formal risk-acceptance agreement with the vendor, establish compensatory network-level controls (such as port blocking or encrypted tunnels), and submit this mitigation strategy to the FDA to demonstrate that the unmapped third-party software does not introduce unmanaged pathways for lateral movement.

Managing a medical device software supply chain is ultimately an exercise in operational discipline rather than technological wizardry. The manufacturers that successfully navigate this transition are not those searching for a perfect, automated silver bullet, but those that build quiet, repeatable systems to normalize their data, triage their vulnerabilities, and systematically eliminate their technical debt.

How many active, unmapped open-source dependencies are currently compiled into your flagship connected device's firmware?

Related from this blog

Sources

Next Post Previous Post
No Comment
Add Comment
comment url